EMB
VRTX icon

Elefante Mark B’s Vertex Pharmaceuticals VRTX Stock Holding History

Elefante Mark B’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.64M Buy
8,141
+1,126
+16% +$525K 2% 24
2025
Q4 		$3.18M Buy
7,015
+352
+5% +$152K 1.95% 22
2025
Q3 		$2.61M Buy
6,663
+831
+14% +$347K 1.67% 25
2025
Q2 		$2.6M Buy
5,832
+171
+3% +$78.8K 1.95% 25
2025
Q1 		$2.74M Buy
5,661
+1,109
+24% +$517K 2.17% 25
2024
Q4 		$1.83M Buy
+4,552
New +$2.11M 1.67% 26

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Elefante Mark B's VRTX Position: Q1 2026 in Review

Elefante Mark B increased its Vertex Pharmaceuticals (VRTX) stake by 16% in Q1 2026, buying an estimated $525K and bringing the position to 8,141 shares worth $3.64M. The position accounts for 2% of the portfolio, ranked #24.

Elefante Mark B first reported a position in VRTX in Q4 2024 and has held it in 6 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Elefante Mark B held 8,141 shares of Vertex Pharmaceuticals worth $3.64M as of Q1 2026.
  • Elefante Mark B bought 1,126 Vertex Pharmaceuticals shares in Q1 2026, an estimated $525K.
  • Vertex Pharmaceuticals made up 2% of Elefante Mark B's portfolio in Q1 2026, its #24 holding.
  • Elefante Mark B first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Elefante Mark B's 13F filing for Q1 2026, filed 15 May 2026.